AXSM Axsome Therapeutics, Inc.
Price Chart
Executive Summary
Axsome Therapeutics adopted a formal Executive Severance and Change in Control Plan effective June 5, 2026, covering the CEO (Tier 1), other Section 16 officers (Tier 2), and VPs+ (Tier 3). The plan provides cash severance of 18/12/6 months' base salary outside a change of control, and 24/18/9 months' salary plus target bonus, full equity acceleration, and COBRA payments upon a qualifying termination during a change of control period. This is a routine adoption of a standardized severance framework that supersedes prior individual agreements, with no departure or appointment of any officer.
Actionable Insight
This is a routine governance filing with no immediate trading implications. Monitor for any future executive departures or change-of-control events that would trigger the severance provisions, but no catalyst is present today.
Key Facts
- Plan adopted June 5, 2026, approved by Compensation Committee
- CEO (Tier 1) gets 18 months base salary severance outside CIC, 24 months plus target bonus and full equity vesting during CIC period
- Other Section 16 officers (Tier 2) get 12 months base salary outside CIC, 18 months plus target bonus and full equity vesting during CIC period
- VPs+ (Tier 3) get 6 months base salary outside CIC, 9 months plus target bonus and full equity vesting during CIC period
- Plan supersedes all prior severance arrangements in employment agreements
- No officer departures or appointments were announced
Financial Impact
No specific dollar amounts disclosed; severance is formula-based on base salary and target bonus. The plan is unfunded and paid from general assets.
Risk Factors
- No material risks identified from this filing alone
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-264047 |
| Document: axsm-20260605.htm | 0001193125-26-264047 |
| Document: 0001193125-26-264047-index-headers.html | 0001193125-26-264047 |
| Document: 0001193125-26-264047-index.html | 0001193125-26-264047 |
| Document: 0001193125-26-264047.txt | 0001193125-26-264047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
Insider Cluster
| $253.88 awaiting T+1 | awaiting T+1 | — | $255.17 (+0.51%) |
|
Jun 11, 2026
1d ago
|
144
| $253.88 awaiting T+1 | awaiting T+1 | — | $255.17 (+0.51%) |
|
Jun 11, 2026
2d ago
|
Insider Cluster
| $246.42 awaiting T+1 | awaiting T+1 | — | $255.17 (+3.55%) |
|
Jun 9, 2026
3d ago
|
144
| $245.68 awaiting T+1 | awaiting T+1 | — | $255.17 (+3.86%) |
|
Jun 9, 2026
3d ago
|
8-K
| $245.68 awaiting T+1 | awaiting T+1 | — | $255.17 (+3.86%) |
|
Jun 9, 2026
3d ago
|
Insider Cluster
| $245.68 awaiting T+1 | awaiting T+1 | — | $255.17 (+3.86%) |
|
Jun 4, 2026
9d ago
|
Press Release
| $231.48 $232.32 | ▲ +0.36% | ▲ +2.96% | $255.17 (+10.23%) |
|
Jun 3, 2026
10d ago
|
8-K
| $233.49 $231.48 | ▼ −0.86% | ▼ −1.26% | $255.17 (+9.29%) |
|
May 4, 2026
5w ago
|
8-K
| $223.70 $223.06 | ▼ −0.29% | ▼ −1.08% | $255.17 (+14.07%) |
|
May 4, 2026
5w ago
|
Press Release
| $223.70 $223.06 | ▼ −0.29% | ▼ −1.08% | $255.17 (+14.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access